All-optical Plastic

With the official implementation of the 2025 National Reimbursement Drug List, the targeted new drug teprotumumab injection has been included in medical insurance reimbursement for the first time, thoroughly breaking the limitations of conventional therapies for thyroid eye disease. Leveraging its specialized clinical strengths, the General Ophthalmology Department at Humen Aier Eye Hospital in Dongguan has taken the lead in introducing this insurance‑covered targeted agent locally. Patients suffering from proptosis and diplopia can now access affordable targeted therapy right in their hometown, bringing new hope for globe recession and symptom improvement.

Globally, as electronic screens permeate every aspect of life and work, the demographic affected by dry eye disease keeps growing and getting younger. This is not merely a public‑health concern, but also a practical challenge bearing on countless people’s quality of life and work efficiency. Recently, a technical upgrade for precise ocular‑surface anti‑inflammatory treatment has been launched in Humen, Dongguan. Lifitegrast eye drops, a dry‑eye therapeutic agent with a brand‑new mechanism of action, has been officially put into clinical use at Humen Aier Eye Hospital, bringing hope for faster symptom relief for local patients with moderate‑to‑severe dry eye disease.

On August 8, 2026, the "Five Years, We Witness Each Other" Adolescent Myopia‑Prevention Expert Meet‑and‑Greet was successfully held. Experts and scholars in ophthalmology together with hospital leaders gathered at the event. They joined numerous patient families for a heart‑warming gathering, looking back on Humen Aier Eye Hospital’s fruitful endeavours in eye‑health care and embarking hand‑in‑hand on a new journey of eye‑health protection.

To further enhance standardized diagnosis and treatment capabilities for refractive cataract among ophthalmologists in Dongguan, promote new clinical techniques for complex eye conditions including cataract combined with high myopia, glaucoma and presbyopia correction, and strengthen grassroots ophthalmic medical services, the Dongguan‑level Continuing Medical Education Project — Symposium on Advances in Refractive Cataract Treatment was successfully held at Dongguan Humen Aier Eye Hospital on August 7.

The M22 device featuring optimized OPT intense pulsed light technology has been officially installed at Humen Aier Eye Hospital! The arrival of this brand‑new equipment ushers in a new phase for our hospital’s dry‑eye diagnosis and treatment, offering a more effective new treatment option for patients suffering from dry eye.